AstraZeneca
Enhanced Manufacturing Efforts by Sanofi and AstraZeneca Aim to Prevent Beyfortus Shortfalls in 2024
Beyfortus, RSV prevention, monoclonal antibody, Sanofi, AstraZeneca, manufacturing efforts, supply chain management
AstraZeneca’s Fasenra Gains FDA Approval for Eosinophilic Granulomatosis with Polyangiitis, Expanding Treatment Options for Rare Autoimmune Disease
AstraZeneca, Fasenra, FDA approval, eosinophilic granulomatosis with polyangiitis (EGPA), rare autoimmune disease, biologic treatment, asthma medication, GSK’s Nucala
AstraZeneca’s Imfinzi Demonstrates Significant Survival Benefit in Muscle-Invasive Bladder Cancer, Raises Questions on FDA Approval for Perioperative Design
AstraZeneca, Imfinzi, durvalumab, muscle-invasive bladder cancer, MIBC, perioperative trial design, FDA approval, survival benefit
AstraZeneca Unveils In-House ADCs, Rivaling AbbVie and Pfizer’s Cancer Therapies
AstraZeneca, Daiichi Sankyo, Antibody-Drug Conjugates (ADCs), Cancer Therapies, AbbVie, Pfizer, Oncology, Biotechnology
ESMO24: AstraZeneca’s Imfinzi and Imjudo Combination Doubles 5-Year Overall Survival Rate in Advanced Liver Cancer
AstraZeneca, Imfinzi (durvalumab), Imjudo (tremelimumab), Advanced Liver Cancer, Unresectable Hepatocellular Carcinoma (HCC), 5-Year Overall Survival Rate, ESMO24
AstraZeneca’s Imfinzi Demonstrates Significant Survival Benefits in Muscle-Invasive Bladder Cancer
AstraZeneca, Imfinzi (durvalumab), Muscle-Invasive Bladder Cancer (MIBC), Perioperative Treatment, Event-Free Survival (EFS), Overall Survival (OS), NIAGARA Phase III Trial
AstraZeneca and Daiichi Sankyo’s Dato-DXd Fails to Meet Overall Survival Goal in NSCLC Study, FDA Decision Looms
AstraZeneca, Daiichi Sankyo, Dato-DXd (datopotamab deruxtecan), Non-small cell lung cancer (NSCLC), Overall survival (OS), FDA decision, TROPION-Lung01 study
AstraZeneca Refines NSCLC Treatment Strategies with Biomarker-Driven Approaches
NSCLC, biomarkers, targeted therapy, immunotherapy, AstraZeneca, lung cancer treatment
AstraZeneca’s IL-33 Drug Shows Mixed Results in COPD Trials, Despite Phase 2 Setbacks
AstraZeneca, IL-33, COPD, tozorakimab, phase 2 trials, respiratory diseases
AstraZeneca and Gilead Explore TROP2 ADCs in Lung Cancer, Seeking Pathways to Approval
TROP2 ADCs, Lung Cancer, AstraZeneca, Gilead, Datopotamab Deruxtecan, Trodelvy, Non-Small Cell Lung Cancer (NSCLC)